Three-Dimensional-Printed Isoniazid Chewable Gels for On-Demand Latent Tuberculosis Treatment in Children.

Publication date: May 17, 2025

Background/Objectives: Pediatric drug administration is hindered by difficulties in swallowing conventional medications and the unpalatable taste of many drugs. Among diseases highlighting the need for improved pediatric delivery, tuberculosis (TB) stands out. One form of the disease is latent TB infection (LTBI), which is concerning in children. Effective LTBI treatment is crucial for prevention, with isoniazid (INH) widely used for its proven efficacy and safety. This study aims to develop innovative 3D-printed chewable gels containing INH for LTBI treatment. Methods: The gels were formulated using gelatin and carrageenan gum, sugar-free sweeteners, and flavoring. Two batches were prepared, and using 3D printing (3DP) with a semi-solid extrusion (SSE) module, chewable gels were produced. Rheological properties were measured to assess the feasibility of 3DP-SSE, evaluating the structural integrity and adequate fluidity of the formulation. The 3D-printed chewable gels were evaluated by visual, mass, and dimensional characteristics. In addition, the water activity, texture profile, INH and degradation product content, in vitro release, and taste-masking were investigated. Results: The optimized formulation maintained suitable rheological properties for 3DP-SSE, demonstrating consistent weight, dimensions, and stability after the process. The texture achieved a balance between printing parameters and shape maintenance, and the INH presented an immediate-release profile (>85% within 30 min). The chewable gels showed an improvement in palatability compared to conventional INH tablets. Conclusions: This innovative approach offers a promising solution for pediatric LTBI treatment, as it improves efficacy, medication acceptability, and on-demand access.

Open Access PDF

Concepts Keywords
Free 3D printing
Gelatin chewable gels
Pharmaceutics isoniazid
Sugar pediatric medicines
Tuberculosis pharmaceutical manufacturing
rheology
semi-solid extrusion
tuberculosis

Semantics

Type Source Name
drug DRUGBANK Isoniazid
disease MESH Latent Tuberculosis
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH infection
drug DRUGBANK Gelatin
drug DRUGBANK Water
pathway REACTOME Release
disease IDO process
drug DRUGBANK Isoxaflutole
drug DRUGBANK Ribostamycin
drug DRUGBANK Coenzyme M
disease MESH latent infection
disease MESH bacterial infection
disease MESH death
disease IDO infectious agent
drug DRUGBANK Rifapentine
drug DRUGBANK Rifampicin
disease MESH anaphylaxis
drug DRUGBANK Alpha-1-proteinase inhibitor
disease IDO production
disease IDO quality
drug DRUGBANK Xylitol
disease MESH ramp
drug DRUGBANK Nitrogen
drug DRUGBANK Aluminium
disease IDO host
drug DRUGBANK Alteplase
drug DRUGBANK Phosphate ion
drug DRUGBANK Aminohippuric acid
drug DRUGBANK Silver
drug DRUGBANK Gold
drug DRUGBANK Pidolic Acid
drug DRUGBANK Aspartame
drug DRUGBANK Aminosalicylic Acid
disease MESH defects
disease MESH choking
drug DRUGBANK Methionine
disease IDO blood
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Pyrazinamide
drug DRUGBANK L-Isoleucine
drug DRUGBANK Ascorbic acid
disease MESH Syndrome
drug DRUGBANK Praziquantel
drug DRUGBANK Chloroquine
drug DRUGBANK Polyvinyl alcohol
drug DRUGBANK Zinc
drug DRUGBANK Hydroxide ion
drug DRUGBANK Pectin
disease MESH Necrosis
disease MESH Hepatitis
disease MESH Cirrhosis
disease MESH Hemorrhage
disease MESH Esophageal Varices

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *